{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:20:09Z","timestamp":1771942809544,"version":"3.50.1"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To discuss the varies outcome measure instruments for the assessment of different domains for psoriatic arthritis (PsA) both in trial and clinical practice settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>PsA is a multifaceted chronic inflammatory disease with diverse manifestations. This pose challenges of comprehensive assessment of the outcome of PsA. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) had developed the core domain set and in the progress of selecting the core outcome measurement set for trials and clinical practice for PsA, using the framework set by Outcome Measures in Rheumatology (OMERACT). In brief, the core set of \u201cwhat to measure\u201d has been endorsed, and a standardized way of \u201chow to measure\u201d them are under review. Composite outcome measures for PsA may provide a solution to measuring multiple domains in a nutshell for various purposes in trials and clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>This provides a succinct summary of the current state of outcome measurement in PsA and provides a quick and comprehensive perspective to select relevant outcome measure to use in busy rheumatology clinical settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001089","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T11:01:11Z","timestamp":1741690871000},"page":"233-242","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Monitoring psoriatic arthritis in research and clinical practice"],"prefix":"10.1097","volume":"37","author":[{"given":"Yu Heng","family":"Kwan","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Singapore General Hospital"},{"name":"Program in Health Services and Systems Research, Duke-NUS Medical School"},{"name":"Centre of Population Health and Implementation Research, SingHealth Regional Health System"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying Ying","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Singapore General Hospital"},{"name":"Duke-NUS Medical School, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/art.40695","article-title":"Effect of achieving minimal disease activity on the progression of subclinical atherosclerosis and arterial stiffness: a prospective cohort study in psoriatic arthritis","volume":"71","author":"Cheng","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.200121","article-title":"Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership-recommended next steps","volume":"96","author":"Tillett","year":"2020","journal-title":"J Rheumatol Suppl"},{"key":"R7-20250604","first-page":"198","article-title":"The OMERACT filter for outcome measures in rheumatology","volume":"25","author":"Boers","year":"1998","journal-title":"J Rheumatol"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","article-title":"Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0","volume":"67","author":"Boers","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis es"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fmed.2018.00246","article-title":"Classification and outcome measures for psoriatic arthritis","volume":"5","author":"Leung","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1136\/annrheumdis-2017-212004","article-title":"GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies","volume":"77","author":"Tillett","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.semarthrit.2021.08.011","article-title":"The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2","volume":"51","author":"Maxwell","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3899\/jrheum.181089","article-title":"Endorsement of the 66\/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 psoriatic arthritis workshop report","volume":"46","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"J Rheumatol"},{"key":"R14-20250604","first-page":"1159","article-title":"Outcome measures in psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"e000486","DOI":"10.1136\/rmdopen-2017-000486","article-title":"Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis","volume":"3","author":"Michelsen","year":"2017","journal-title":"RMD Open"},{"issue":"(Suppl 2)","key":"R16-20250604","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.2023-0530","article-title":"Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT working group","volume":"50","author":"Leung","year":"2023","journal-title":"J Rheumatol"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.46.3.197","article-title":"Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis","volume":"46","author":"Mander","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3899\/jrheum.171466","article-title":"Psoriatic arthritis sonographic enthesitis instruments: a systematic review of the literature","volume":"46","author":"Elalouf","year":"2019","journal-title":"J Rheumatol"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R21-20250604","first-page":"299","article-title":"Greater magnitude of entheseal microdamage and repair in psoriatic arthritis compared with ankylosing spondylitis on ultrasound","volume":"58","author":"Arslan Alhussain","year":"2019","journal-title":"Rheumatology"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3899\/jrheum.200128","article-title":"Development and validation of a sonographic enthesitis instrument in psoriatic arthritis: the GRAPPA Diagnostic Ultrasound Enthesitis Tool (DUET) project","volume":"96","author":"Eder","year":"2020","journal-title":"J Rheumatol Suppl"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","article-title":"Dactylitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard.2003.018184","article-title":"Dactylitis in psoriatic arthritis: a marker for disease severity?","volume":"64","author":"Brockbank","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10067-019-04683-2","article-title":"Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis","volume":"39","author":"Girolimetto","year":"2020","journal-title":"Clin rheumatol"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"rkae058","DOI":"10.1093\/rap\/rkae058","article-title":"BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies","volume":"8","author":"Baraliakos","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jaad.2014.11.002","article-title":"The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology","volume":"72","author":"Gottlieb","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/17512433.2020.1743175","article-title":"Evolution of the inclusion\/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis","volume":"13","author":"Hsu","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/ced.15148","article-title":"Estimation error of the body surface area in psoriasis: a comparative study of physician and computer-assisted image analysis (ImageJ)","volume":"47","author":"Yoo","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"(S11)","key":"R31-20250604","first-page":"S64","article-title":"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy\u2013Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-019-00496-w","article-title":"Investigator and patient global assessment measures for psoriasis clinical trials: a systematic review on measurement properties from the international dermatology outcome measures (IDEOM) initiative","volume":"21","author":"Perez-Chada","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.jid.2018.01.041","article-title":"Evaluation of sPGA\u200a\u00d7\u200aBSA as an outcome measure and treatment target for clinical practice","volume":"138","author":"Merola","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09593980600564493","article-title":"Use of the faces pain scale to evaluate pain of a pediatric patient with pauciarticular juvenile rheumatoid arthritis","volume":"22","author":"Metivier","year":"2006","journal-title":"Physiother Theory Pract"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3899\/jrheum.141386","article-title":"Harmonizing pain outcome measures: results of the Pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the cochrane musculoskeletal group and OMERACT","volume":"42","author":"Phillips","year":"2015","journal-title":"J Rheumatol"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"152423","DOI":"10.1016\/j.semarthrit.2024.152423","article-title":"Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets","volume":"66","author":"Maxwell","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.100857","article-title":"Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study","volume":"38","author":"Cauli","year":"2011","journal-title":"J Rheumatol"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.semarthrit.2021.07.014","article-title":"OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF","volume":"51","author":"Leung","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.semarthrit.2020.05.022","article-title":"Clinical trial discrimination of physical function instruments for psoriatic arthritis: a systematic review","volume":"50","author":"Leung","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R42-20250604","article-title":"Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: a meta-epidemiological study","author":"Ying-Ying Leung","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"R43-20250604","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3899\/jrheum.191119","article-title":"Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis","volume":"48","author":"Leung","year":"2021","journal-title":"J Rheumatol"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/A:1012588218728","article-title":"Interpreting SF-36 summary health measures: a response","volume":"10","author":"Ware","year":"2001","journal-title":"Qual Life Res"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3899\/jrheum.181077","article-title":"PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials","volume":"46","author":"Orbai","year":"2019","journal-title":"J Rheumatol"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s42358-020-00149-1","article-title":"Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease","volume":"60","author":"da Cruz Ribeiro e Souza","year":"2020","journal-title":"Adv Rheumatol"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"e001321","DOI":"10.1136\/rmdopen-2020-001321","article-title":"Patient's experience of psoriatic arthritis: a conceptual model based on qualitative interviews","volume":"6","author":"Ogdie","year":"2020","journal-title":"RMD Open"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3899\/jrheum.200127","article-title":"The GRAPPA-OMERACT Working Group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates","volume":"96","author":"Leung","year":"2020","journal-title":"J Rheumatol Suppl"},{"key":"R52-20250604","first-page":"S177","article-title":"Validation and normative data for the 0-10 point scale version of the Fatigue Severity Scale (FSS)","author":"Schentag","year":"2000","journal-title":"Arthritis Rheumatol"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/ard.2006.065763","article-title":"Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis","volume":"66","author":"Chandran","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.semarthrit.2017.09.002","article-title":"A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative","volume":"47","author":"H\u00f8jgaard","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"e000928","DOI":"10.1136\/rmdopen-2019-000928","article-title":"Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis","volume":"6","author":"Gladman","year":"2020","journal-title":"RMD open"},{"issue":"(Suppl 1)","key":"R56-20250604","first-page":"52","article-title":"Laboratory findings in psoriatic arthritis","volume":"59","author":"Punzi","year":"2007","journal-title":"Reumatismo"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3899\/jrheum.180195","article-title":"Using acute-phase reactants to inform the development of instruments for the updated psoriatic arthritis core outcome measurement Set","volume":"46","author":"Elmamoun","year":"2019","journal-title":"J Rheumatol"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"e001756","DOI":"10.1136\/rmdopen-2021-001756","article-title":"Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?","volume":"8","author":"Houttekiet","year":"2022","journal-title":"RMD Open"},{"issue":"(Suppl 1)","key":"R59-20250604","first-page":"13","article-title":"Basic science session 1. biomarkers for psoriatic arthritis treatment response and joint damage progression: an update on 2 industry-GRAPPA projects","volume":"49","author":"Waddington","year":"2022","journal-title":"J Rheumatol"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3899\/jrheum.160904","article-title":"Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT","volume":"44","author":"Orbai","year":"2017","journal-title":"J Rheumatol"},{"issue":"(Suppl 1)","key":"R61-20250604","first-page":"20","article-title":"Plain radiographic instruments for structural damage in peripheral joints in psoriatic arthritis: a report from the GRAPPA-OMERACT working group","volume":"49","author":"Antony","year":"2022","journal-title":"J Rheumatol"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2021.01.008","article-title":"Measurement properties of radiographic outcome measures in psoriatic arthritis: a systematic review from the GRAPPA-OMERACT initiative","volume":"51","author":"Antony","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.semarthrit.2021.11.001","article-title":"Composite outcomes at OMERACT: multioutcome domains and composite outcome domains","volume":"51","author":"Wells","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.3390\/jcm12134371","article-title":"Making sense of composite endpoints in clinical research","volume":"12","author":"Baracaldo-Santamar\u00eda","year":"2023","journal-title":"J Clin Med"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","article-title":"Development of a preliminary composite disease activity index in psoriatic arthritis","volume":"70","author":"Mumtaz","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R67-20250604","article-title":"Composite outcome measures for psoriatic arthritis: project updates","author":"Ribeiro","year":"2024","journal-title":"J Rheumatol"},{"key":"R68-20250604","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R70-20250604","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2018-214140","article-title":"Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries","volume":"78","author":"Gorlier","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R72-20250604","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1093\/rheumatology\/keab220","article-title":"What influences patients\u2019 opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study","volume":"60","author":"Coates","year":"2021","journal-title":"Rheumatology"},{"key":"R73-20250604","article-title":"Composite measures for routine clinical practice in psoriatic arthritis: testing of shortened versions in a UK Multicenter Study","author":"Tillett","year":"2021","journal-title":"J Rheumatoal"},{"issue":"(Suppl 2)","key":"R74-20250604","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3899\/jrheum.2024-0515","article-title":"Composite outcome measures for psoriatic arthritis: OMERACT and 3 and 4 visual analog scale progress in","volume":"51","author":"Leung","year":"2024","journal-title":"J Rheumatol"},{"key":"R75-20250604","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40744-024-00690-1","article-title":"Filling the \u201cGAP\u201d in real-world assessment of psoriatic arthritis disease activity: performance characteristics of a global\/pain composite endpoint","volume":"11","author":"Tillett","year":"2024","journal-title":"Rheumatol Ther"},{"key":"R76-20250604","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acr.24433","article-title":"Measurement of minimal disease activity in psoriatic arthritis using the patient-reported outcomes measurement information system-physical function or the health assessment questionnaire disability index","volume":"74","author":"Chew","year":"2022","journal-title":"Arthritis Care Res"},{"key":"R77-20250604","doi-asserted-by":"crossref","first-page":"e0253615","DOI":"10.1371\/journal.pone.0253615","article-title":"Electronic patient-reported outcome measures using mobile health technology in rheumatology: a scoping review","volume":"16","author":"Shelton","year":"2021","journal-title":"PLoS One"},{"key":"R78-20250604","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/art.42559","article-title":"The clinical impact of electronic patient-reported outcome measures in the remote monitoring of inflammatory arthritis: a systematic review and meta-analysis","volume":"75","author":"Arumalla","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R79-20250604","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/acr.23768","article-title":"Detection of flares by decrease in physical activity, collected using wearable activity trackers in rheumatoid arthritis or axial spondyloarthritis: an application of machine learning analyses in rheumatology","volume":"71","author":"Gossec","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R80-20250604","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.2196\/mhealth.9656","article-title":"Using a researchkit smartphone app to collect rheumatoid arthritis symptoms from real-world participants: feasibility study","volume":"6","author":"Crouthamel","year":"2018","journal-title":"JMIR Mhealth Uhealth"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:00:40Z","timestamp":1749013240000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001089","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]}}}